Synergy Spine Solutions completed enrollment in its first-ever Investigational Device Exemption (IDE) clinical trial.
The 1-Level Synergy Disc IDE clinical trial enrolled 175 patients in its multi-center, prospective, historically-controlled pivotal trial comparing the safety and effectiveness of the Synergy Disc to anterior cervical discectomy and fusion in patients with one-level symptomatic cervical degenerative disc disease. The study is being conducted at 20 sites across the United States and will be used to support a premarket approval application in the U.S.
Josh Butters, Synergy Spine Solutions CEO, said, “We are excited to continue following these patients, further building Synergy’s clinical evidence, and advancing our pre-market approval strategy for the Synergy Disc in the U.S.”
Synergy Spine Solutions completed enrollment in its first-ever Investigational Device Exemption (IDE) clinical trial.
The 1-Level Synergy Disc IDE clinical trial enrolled 175 patients in its multi-center, prospective, historically-controlled pivotal trial comparing the safety and effectiveness of the Synergy Disc to anterior cervical...
Synergy Spine Solutions completed enrollment in its first-ever Investigational Device Exemption (IDE) clinical trial.
The 1-Level Synergy Disc IDE clinical trial enrolled 175 patients in its multi-center, prospective, historically-controlled pivotal trial comparing the safety and effectiveness of the Synergy Disc to anterior cervical discectomy and fusion in patients with one-level symptomatic cervical degenerative disc disease. The study is being conducted at 20 sites across the United States and will be used to support a premarket approval application in the U.S.
Josh Butters, Synergy Spine Solutions CEO, said, “We are excited to continue following these patients, further building Synergy’s clinical evidence, and advancing our pre-market approval strategy for the Synergy Disc in the U.S.”
Copy to clipboard 
